Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BEIJING ENTPS H/S stock logo
BJINY
BEIJING ENTPS H/S
$57.62
$57.62
$46.69
▼
$57.69
$7.27B1.26250 shs82 shs
Showa Denko Materials Co., Ltd. stock logo
HCHMY
Showa Denko Materials
$87.14
$87.14
$55.04
▼
$93.00
$9.08B0.72467 shs7 shs
HOPEWELL HOLDIN/ADR stock logo
HOWWY
HOPEWELL HOLDIN/ADR
$4.80
-0.4%		$4.80
$2.98
▼
$5.10
$4.17B0.2559,119 shs2,500 shs
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
$24.38
-1.2%		$24.38
$18.50
▼
$31.96
$6.64B1.811,665 shs200 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BEIJING ENTPS H/S stock logo
BJINY
BEIJING ENTPS H/S
0.00%0.00%0.00%0.00%0.00%
Showa Denko Materials Co., Ltd. stock logo
HCHMY
Showa Denko Materials
0.00%0.00%0.00%0.00%0.00%
HOPEWELL HOLDIN/ADR stock logo
HOWWY
HOPEWELL HOLDIN/ADR
0.00%0.00%0.00%0.00%0.00%
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BEIJING ENTPS H/S stock logo
BJINY
BEIJING ENTPS H/S
$57.62
$57.62
$46.69
▼
$57.69
$7.27B1.26250 shs82 shs
Showa Denko Materials Co., Ltd. stock logo
HCHMY
Showa Denko Materials
$87.14
$87.14
$55.04
▼
$93.00
$9.08B0.72467 shs7 shs
HOPEWELL HOLDIN/ADR stock logo
HOWWY
HOPEWELL HOLDIN/ADR
$4.80
-0.4%		$4.80
$2.98
▼
$5.10
$4.17B0.2559,119 shs2,500 shs
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
$24.38
-1.2%		$24.38
$18.50
▼
$31.96
$6.64B1.811,665 shs200 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BEIJING ENTPS H/S stock logo
BJINY
BEIJING ENTPS H/S
0.00%0.00%0.00%0.00%0.00%
Showa Denko Materials Co., Ltd. stock logo
HCHMY
Showa Denko Materials
0.00%0.00%0.00%0.00%0.00%
HOPEWELL HOLDIN/ADR stock logo
HOWWY
HOPEWELL HOLDIN/ADR
0.00%0.00%0.00%0.00%0.00%
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BEIJING ENTPS H/S stock logo
BJINY
BEIJING ENTPS H/S
0.00
N/AN/AN/A
Showa Denko Materials Co., Ltd. stock logo
HCHMY
Showa Denko Materials
0.00
N/AN/AN/A
HOPEWELL HOLDIN/ADR stock logo
HOWWY
HOPEWELL HOLDIN/ADR
0.00
N/AN/AN/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BEIJING ENTPS H/S stock logo
BJINY
BEIJING ENTPS H/S
$7.38B0.99$10.55 per share5.46$80.49 per share0.72
Showa Denko Materials Co., Ltd. stock logo
HCHMY
Showa Denko Materials
$5.81B1.56$5.33 per share16.35$38.20 per share2.28
HOPEWELL HOLDIN/ADR stock logo
HOWWY
HOPEWELL HOLDIN/ADR
$253.58M16.46$0.20 per share24.02$7.76 per share0.62
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
$763.19M8.71$0.70 per share34.66$2.88 per share8.47
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BEIJING ENTPS H/S stock logo
BJINY
BEIJING ENTPS H/S
$882.75M$6.998.247.13N/AN/AN/AN/AN/A
Showa Denko Materials Co., Ltd. stock logo
HCHMY
Showa Denko Materials
$150.89M$1.4559.69N/AN/A2.60%3.82%2.31%N/A
HOPEWELL HOLDIN/ADR stock logo
HOWWY
HOPEWELL HOLDIN/ADR
$1.15BN/AN/AN/AN/AN/AN/AN/AN/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
$134.73M$0.5048.7616.931.3025.75%29.63%18.74%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BEIJING ENTPS H/S stock logo
BJINY
BEIJING ENTPS H/S
$0.781.35%N/A11.16%N/A
Showa Denko Materials Co., Ltd. stock logo
HCHMY
Showa Denko Materials
N/AN/AN/AN/AN/A
HOPEWELL HOLDIN/ADR stock logo
HOWWY
HOPEWELL HOLDIN/ADR
$0.122.50%N/AN/AN/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BEIJING ENTPS H/S stock logo
BJINY
BEIJING ENTPS H/S
N/AN/AN/A
Showa Denko Materials Co., Ltd. stock logo
HCHMY
Showa Denko Materials
0.14
1.84
1.38
HOPEWELL HOLDIN/ADR stock logo
HOWWY
HOPEWELL HOLDIN/ADR
0.03
15.69
15.69
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
BEIJING ENTPS H/S stock logo
BJINY
BEIJING ENTPS H/S
0.01%
Showa Denko Materials Co., Ltd. stock logo
HCHMY
Showa Denko Materials
N/A
HOPEWELL HOLDIN/ADR stock logo
HOWWY
HOPEWELL HOLDIN/ADR
N/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/A

Insider Ownership

CompanyInsider Ownership
BEIJING ENTPS H/S stock logo
BJINY
BEIJING ENTPS H/S
N/A
Showa Denko Materials Co., Ltd. stock logo
HCHMY
Showa Denko Materials
N/A
HOPEWELL HOLDIN/ADR stock logo
HOWWY
HOPEWELL HOLDIN/ADR
N/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
BEIJING ENTPS H/S stock logo
BJINY
BEIJING ENTPS H/S
45,000126.21 millionN/ANot Optionable
Showa Denko Materials Co., Ltd. stock logo
HCHMY
Showa Denko Materials
23,095104.18 millionN/ANot Optionable
HOPEWELL HOLDIN/ADR stock logo
HOWWY
HOPEWELL HOLDIN/ADR
1,052869.84 millionN/ANot Optionable
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
902272.51 millionN/ANot Optionable

Recent News About These Companies

Swedish Orphan Biovitrum AB: New analysis shows Tryngolza (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia
May 26, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68596754-swedish-orphan-biovitrum-ab-new-analysis-shows-tryngolza-olezarsen-reduced-acute-pancreatitis-by-85-and-triglycerides-by-66-in-severe-hypertrigly-008.htm
Swedish Orphan Biovitrum Receives Health Canada Approval for EMPAVELI (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
April 28, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68166531-swedish-orphan-biovitrum-receives-health-canada-approval-for-empaveli-pegcetacoplan-for-the-treatment-of-c3g-and-primary-ic-mpgn-399.htm
Swedish Orphan Biovitrum AB: EMA validates indication extension application for Tryngolza (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)
March 31, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/68070631-swedish-orphan-biovitrum-ab-ema-validates-indication-extension-application-for-tryngolza-olezarsen-for-the-treatment-of-severe-hypertriglyceridemia-008.htm
Positive results for Sobi’s emapalumab in sepsis
March 18, 2026  |  thepharmaletter.comT
Swedish Orphan Biovitrum AB: Sobi to Showcase Scientific advances and Commitment to the Haemophilia community at EAHAD 2026
February 3, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67597324-swedish-orphan-biovitrum-ab-sobi-to-showcase-scientific-advances-and-commitment-to-the-haemophilia-community-at-eahad-2026-008.htm
Swedish Orphan Biovitrum AB: Sobi Receives European Commission Approval for Aspaveli (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
January 16, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-01/67453957-swedish-orphan-biovitrum-ab-sobi-receives-european-commission-approval-for-aspaveli-pegcetacoplan-for-the-treatment-of-c3g-and-primary-ic-mpgn-008.htm
Swedish Orphan Biovitrum AB: Sobi's 2025 annual revenue and adjusted EBITA margin exceed previous outlook
January 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-01/67443316-swedish-orphan-biovitrum-ab-sobi-s-2025-annual-revenue-and-adjusted-ebita-margin-exceed-previous-outlook-008.htm
Swedish Orphan Biovitrum AB completes key study on Still’s disease in Italy
December 14, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/swedish-orphan-biovitrum-ab-completes-key-study-on-still-s-disease-in-italy/ar-AA1Skwhg
Swedish Orphan Biovitrum AB: Sobi Receives Positive CHMP Opinion for Aspaveli (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
December 12, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-12/67220086-swedish-orphan-biovitrum-ab-sobi-receives-positive-chmp-opinion-for-aspaveli-pegcetacoplan-for-the-treatment-of-c3g-and-primary-ic-mpgn-008.htm
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
October 19, 2025  |  prnewswire.co.ukP
Sobi and Ionis win EU approval for Tryngolza in FCS
September 19, 2025  |  thepharmaletter.comT
Swedish Orphan Biovitrum AB: FDA Accepts Biologics License Application for Sobi's NASP for Patients with Uncontrolled Gout
September 10, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-09/66398249-swedish-orphan-biovitrum-ab-fda-accepts-biologics-license-application-for-sobi-s-nasp-for-patients-with-uncontrolled-gout-008.htm
Swedish Drugmaker Sobi Doesn’t See Pharma Tariffs as ‘Imminent’
July 16, 2025  |  bloomberg.comhttps://www.bloomberg.com/news/articles/2025-07-16/swedish-drugmaker-sobi-doesn-t-see-pharma-tariffs-as-imminent
Swedish Orphan Biovitrum AB: Sobi and Apellis: Aspaveli/Empaveli Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases
June 6, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-06/65606921-swedish-orphan-biovitrum-ab-sobi-and-apellis-aspaveli-empaveli-demonstrates-sustained-one-year-efficacy-in-phase-3-study-for-rare-kidney-diseases-008.htm
Swedish health minister pressed to fund orphan drug access
May 30, 2025  |  euractiv.comE
Swedish Orphan Biovitrum AB: Sobi to share new clinical data and research at EULAR 2025
May 28, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-05/65519368-swedish-orphan-biovitrum-ab-sobi-to-share-new-clinical-data-and-research-at-eular-2025-008.htm
Berenberg cuts SOBI stock target to SEK360, maintains buy
April 18, 2025  |  uk.investing.comhttps://uk.investing.com/news/analyst-ratings/berenberg-cuts-sobi-stock-target-to-sek360-maintains-buy-93CH-4033534
Sobi announces a new research collaboration on the development of Gamifant in sepsis, which is to be presented at the ISICEM congress
March 21, 2025  |  pharmabiz.comP
RBC Capital Remains a Buy on Swedish Orphan Biovitrum AB (0MTD)
January 14, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/rbc-capital-remains-a-buy-on-swedish-orphan-biovitrum-ab-0mtd-1034224411
Sobi Announces FDA Acceptance of New Drug Application for Avatrombopag (DOPTELET®) for the Treatment of Pediatric Immune Thrombocytopenia
December 12, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/sobi-announces-fda-acceptance-of-new-drug-application-for-avatrombopag-doptelet-for-the-treatment-of-pediatric-immune-thrombocytopenia-1034129038

Media Sentiment Over Time

BEIJING ENTPS H/S stock logo

BEIJING ENTPS H/S OTCMKTS:BJINY

$57.62 0.00 (0.00%)
As of 04/3/2019

Beijing Enterprises Holdings Limited, an investment holding company, engages in piped gas, brewery, water and environmental, solid waste treatment, and other businesses primarily in Mainland China. Its Piped Gas Operation segment distributes and sells piped natural gas; provides natural gas transmission, and gas technology consultation and development services, as well as repair and maintenance services; surveys and plots underground construction projects; and constructs and installs gas pipelines and related equipment. The company's Brewery Operation segment produces, distributes, and sells brewery products. Its Water and Environmental segment constructs sewage and water treatment plants and other infrastructural facilities; provides construction services for renovation projects; offers sewage treatment, and water treatment and distribution services, as well as consultancy services; and licenses technical know-how related to sewage treatment. The company's Solid Waste Treatment segment is involved in the construction and operation of waste incineration plants; waste treatment; sale of electricity; generation of heat and stream from waste incineration. Its Corporate and Others segment offers consultation and property investment services. Beijing Enterprises Holdings Limited was founded in 1997, and is considered a Red Chip company due to its listing on the Hong Kong Stock Exchange. The company is based in Wan Chai, Hong Kong. Beijing Enterprises Holdings Limited is a subsidiary of Beijing Enterprises Group (BVI) Company Limited.

Showa Denko Materials stock logo

Showa Denko Materials OTCMKTS:HCHMY

$87.14 0.00 (0.00%)
As of 10/28/2020

Showa Denko Materials Co., Ltd. manufactures and sells functional materials, and advanced components and systems in Japan and internationally. The company provides semiconductor related materials, such as chemical mechanical planarization slurry, high heat resistant fine polyimides, photosensitive insulation coatings, die bonding pastes and films, epoxy molding compounds, liquid encapsulants, cleaning sheets, high heat resistant coating materials, map molding support tapes, release sheets, and dicing films; and display and touch panel related materials, including anisotropic conductive films, transparent conductive transfer films, and adhesive films for displays. It also offers photovoltaic related materials comprising conductive films; advanced films, RFID tags, foam products, and food wrap films; lithium-ion batteries materials, carbon brushes, and ceramics; resins, adhesives and tapes, and electrical insulating materials; base and process materials for printed wiring boards (PWBs); and white epoxy molding compounds for LED reflectors. In addition, the company provides automotive products consisting of molded plastics, poly-sheets, carbon sliding materials, SPD films, protective films, automotive batteries, and powder metal products; and industrial batteries and capacitors, as well as electrical equipment, including DC power supply units and systems, and uninterruptible power supply products. Further, it provides PWBs, such as high layer PWBs, high density multi wiring boards, and PWBs for IC testers; allergy diagnostic kits, tear total IgE detection kits, in-vitro diagnostic kits, and exosomal mRNA isolation kits, as well as regenerative medicine contract development and manufacturing services; and golf carts. The company was formerly known as Hitachi Chemical Company, Ltd. The company was founded in 1912 and is headquartered in Tokyo, Japan. As of April 20, 2020, Showa Denko Materials Co., Ltd. operates as a subsidiary of Showa Denko K.K.

HOPEWELL HOLDIN/ADR stock logo

HOPEWELL HOLDIN/ADR OTCMKTS:HOWWY

$4.80 -0.02 (-0.44%)
As of 05/17/2019

Hopewell Holdings Limited (“HHL”), the Hong Kong-based group, was listed on The Stock Exchange of Hong Kong in 1972. HHL and its subsidiaries are active in the fields of property development and investment, investment in infrastructure projects, hotel investment and management, restaurant operations and food catering.

SWEDISH ORPHAN/S stock logo

SWEDISH ORPHAN/S OTCMKTS:SWTUY

$24.38 -0.29 (-1.18%)
As of 04/9/2019

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas